Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055464 | 0.84 | GABRR1 (0.43) | GABRR1 | |
| SCHEMBL70312 | 0.84 | GABRR1 (0.43) | GABRR1 | |
| SCHEMBL8972064 | 0.82 | PPM1B (0.37) | — | |
| SCHEMBL8969007 | 0.77 | POLB (0.33) | — | |
| SCHEMBL8970065 | 0.77 | GRM2 (0.36) | — | |
| SCHEMBL8970200 | 0.77 | PPM1B (0.42) | — | |
| SCHEMBL8970499 | 0.74 | PPM1B (0.45) | — | |
| SCHEMBL4478750 | 0.74 | GABRR1 (0.46) | GABRR1 | |
| SCHEMBL5070654 | 0.74 | GABRR1 (0.46) | GABRR1 | |
| SCHEMBL168962 | 0.74 | GABRR1 (0.46) | GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070771-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10745413-B2 | Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives | VERRICA PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190002474-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS INC. | 2019-01-03 | — | — | US | disclosed |
| EP-3233865-A2 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | Verrica Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100732-A2 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | VERRICA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070771-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | TYR, CHIA, NISCH | GABRR1 4122/4885 |
| US-10745413-B2 | Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives | TYR, CHIA, NISCH | GABRR1 4122/4885 |
| US-20190002474-A1 | COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVES | TYR, CHIA, NISCH | GABRR1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.